A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia

Exclusion Criteria

• •Homozygous familial hypercholesterolaemia, known diagnosis of heterozygous familial hypercholesterolaemia (HeFH), LDL apheresis or plasma apheresis within 12 months prior to screening, or any other underlying known disease or condition that may interfere with interpretation of the clinical study results as judged by the Investigator.
• •Any of the following laboratory values at screening:
• •1. Calculated eGFR \< 15 mL/min/1.73 m2
• •2. AST or ALT \> 3 × ULN
• •3. TBL \> 2 × ULN (except for patients with Gilberts syndrome, where TBL 3 × ULN is acceptable provided direct bilirubin \< 1.5 × ULN)
• •4. Fasting triglycerides ≥ 400 mg/dL (≥ 4.52 mmol/L)
• •5. Creatine kinase \> 5 × ULN
• •6. Urine albumin-to-creatinine ratio ≥ 500 mg/g
• •Uncontrolled type 2 diabetes mellitus defined as HbA1C ≥ 9.5% at screening
• •Inadequately treated hypothyroidism defined as TSH \> 1.5 ULN at screening or participants whose thyroid replacement therapy was initiated or modified within the last 3 months prior to screening
• •Use of mipomersen or lomitapide (cholesterol-lowering medications) within 12 months prior to screening or planned use during the study.
• •Use of gemfibrozil within 1 week prior to screening or planned use during the study.
• •Use of PCSK-9 inhibitors: evolocumab/alirocumab within 12 weeks of the screening visit or planned use during the study or inclisiran within 18 months of the screening visit or planned use during the study. Any other approved PCSK-9 inhibitor use within 5 half-lives prior to the screening visit or planned use during the study.